KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Receivables (2017 - 2025)

Novartis Ag's Receivables history spans 9 years, with the latest figure at $10.1 billion for Q4 2025.

  • For Q4 2025, Receivables rose 18.29% year-over-year to $10.1 billion; the TTM value through Dec 2025 reached $10.1 billion, up 18.29%, while the annual FY2025 figure was $10.1 billion, 18.29% up from the prior year.
  • Receivables for Q4 2025 was $10.1 billion at Novartis Ag, up from $8.5 billion in the prior quarter.
  • Across five years, Receivables topped out at $10.1 billion in Q4 2025 and bottomed at $8.4 billion in Q4 2023.
  • The 5-year median for Receivables is $8.8 billion (2021), against an average of $9.0 billion.
  • The largest annual shift saw Receivables decreased 7.37% in 2023 before it rose 18.29% in 2025.
  • A 5-year view of Receivables shows it stood at $8.8 billion in 2021, then grew by 2.57% to $9.0 billion in 2022, then dropped by 7.37% to $8.4 billion in 2023, then increased by 1.93% to $8.5 billion in 2024, then increased by 18.29% to $10.1 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Receivables are $10.1 billion (Q4 2025), $8.5 billion (Q4 2024), and $8.4 billion (Q4 2023).